CLINICAL PROCEEDINGS

CNSA Clinical Proceedings is a series of educational resources intended to raise awareness about unmet needs in neurology.

White Papers

Alzheimer's Disease Psychosis

CNSA’s inaugural white paper focuses on Alzheimer’s disease psychosis.  

This paper conveys the clinical perspectives as to the challenges in treating patients with Alzheimer’s disease psychosis when no approved therapy is available. The white paper also explores the impact of the unmet needs of Alzheimer’s disease psychosis on patients, clinicians, caregivers and the health care system, as well as societal ramifications. 

 

The expert panel for this paper is: 

  • Howard S. Kirshner, MD – Chair 
  • Jeffrey L. Cummings, MD, ScD
  • Patrick Griffith, MD
  • Christina Mayville, MD   
  • William Petrie, MD

     

The expert panel considered the following topics: 

  • The burden of behavioral and psychological consequences of Alzheimer’s disease. 
  • Factors that increase the burden of Alzheimer’s disease psychosis. 
  • The role of neurologists, geriatric psychiatrists, internists, and geriatricians in treating Alzheimer’s disease psychosis. 
  • The role of caregivers and long-term care clinicians in supporting patients experiencing the disease. 
  • The impact of the lack of approved therapies for Alzheimer’s disease psychosis. 
  • The cost to patients, their families, the health care system and society of untreated Alzheimer’s disease psychosis.

     

The inaugural Clinical Proceedings white paper was supported in part with a grant from Acadia Pharmaceuticals.  

 

If you want to learn more, join CNSA for a webinar about Alzheimer’s disease psychosis on August 19 at 12 pm ET. Learn more and register here.

Pseudobulbar Affect (PBA)

CNSA is planning for the development of its second white paper focused on Pseudobulbar Affect.

The white paper will convey the perspectives of neurologists as to the challenges involved in clinically managing patients with PBA. PBA is a complicated condition that is characterized by episodes of sudden uncontrollable and inappropriate laughing or crying. The current PBA diagnosis and clinical management landscapes have pressing needs. 

CNSA will convene an expert panel to consider, from a clinical perspective, the patient journey of those experiencing PBA. Clinicians will rely on their real-world experience as well as existing research and the perspectives of other stakeholders when developing the publication.

The expert panel will consider the following topics:

  • The growing, yet understudied burden, of PBA on patients’ health status and quality of life
  • The role of neurologists, psychiatrists, internists and primary care providers in diagnosing and clinically managing patients with PBA
  • Barriers to accurate and timely diagnoses of PBA and factors that contribute to misdiagnosis
  • The impact of lack of access to approved treatments for PBA
  • The costs to patients, their families, the health care system and society of untreated BPA.

 

This Clinical Proceedings white paper is being supported in part with a grant from Avanir Pharmaceuticals, Inc.